Purpose: Endoscopic resection is widely accepted as standard treatment for early gastric cancer (EGC) without lymph node metastasis.
Introduction
Early gastric cancer (EGC) is defined as a neoplasm confined to the mucosa or submucosa, regardless of regional lymph node metastasis.(1) EGC without evidence of nodal metastasis is treated by endoscopic resection, either endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD). The endoscopic method is widely accepted because it is less invasive and less costly and requires a shorter hospital stay than surgical resection. (2) (3) (4) Guidelines for EMR/ESD, established by the Japanese Gastric Cancer Association, are generally accepted and state that: 1) elevated EGCs less than 2 cm in diameter and 2) small (≤1 cm) depressed EGCs without ulceration are indications for EMR/ESD. At the same time, these lesions must be differentiated adenocarcinoma confined to the mucosa with no lymphatic or vascular involvement. (5) The so-called extended criteria have been proposed to include: 1) mucosal cancers without ulceration regardless of lesion size, 2) ulcerated mucosal cancers with a size restriction of 30 mm, and 3) cancers with minute submucosal invasion (＜500 μm) with a size restriction of 30 mm. Lesions with undifferentiated histology and lymphatic or vascular invasion are still excluded. (6, 7) Although endoscopic resection has the advantage of preserving most of the stomach and maintaining quality of life, some EMR/ ESD patients have incomplete resections. (8) In addition, EMR/ESD is associated with a complication frequency, particularly perforation and post-operative bleeding (delayed bleeding).(9) The risk of synchronous and metachronous gastric cancer developing in the patient after endoscopic resection has also become a major problem.
(10) Incomplete resection patients are treated empirically, by either gastrectomy, additional endoscopic treatment, or careful follow-up. (11) We conducted this study to evaluate clinical outcomes and the role of surgery for patients with incomplete resection after EMR/ ESD.
Materials and Methods
We retrospectively evaluated 510 gastric cancer patients who underwent EMR/ESD for gastric neoplasm at Korea University 
Results

Reasons for performing gastrectomy after EMR/ESD
The reasons for gastrectomy after EMR/ESD are shown in Table 1 . There was bleeding in 7 cases, metachronous lesion in 3 cases, recurrence in 3 cases, perforation in 2 cases, and lymphatic invasion 1 in case. Curative resection was performed in all patients.
The surgeries performed were subtotal gastrectomy, B-I & B-II and total gastrectomy with Roux-en-Y esophagojejunostomy.
Characteristics of the patients and the gastric lesions in incom- There was 1 case with lymph node metastasis in the positive lateral margin and 2 cases in the positive vertical margin (Table 4) .
We also analyzed the relationship between depth of invasion with residual tumor and lymph node metastasis. One case with residual tumor had submucosal invasion and the other case had muscle invasion. All lymph node metastasis cases were submucosal tumors ( Table 5 ).
Cases of LN metastasis (n=3)
There were 3 cases of LN metastasis. The sizes were 1.5, 1.6, and 2.2 cm.
The histological results were moderately differentiated for case 1, and poorly differentiated in cases 2 and 3. All cases had submucosal invasion. The number of LN metastases were 7, 2, and 1. (Table 6 ).
Cases 1 and 3 had lymphatic invasions and no cases had vascular or neural invasions
Table 3. Endoscopy, EMR/ESD and operative fi ndings
Endoscopy (EUS) EMR/ESD Operation
Depth of invasion 
Discussion
The role of surgery after incomplete EMR/ESD was has been previously reported.
Song et al. (12) reported that gastrectomy with lymph node dissection should be performed in patients with submucosal invasion with or without margin involvement after EMR.
Nagano et al. (13) reported that patients with submucosal invasion or a positive vertical margin should undergo gastrectomy and lymph node dissection.
At first, we expected that if the margin was positive, there'll be residual tumor. But, the results were different. In our study, the positive residual tumor rate was only 15.4% (2 of 13) in positive lateral and/or vertical margin cases. 84.6% (11 of 13) had no residual tumor despite positive margins. In the case that had both the lateral and vertical margins positive, there was no lymph node metastasis.
In a recent study, Chang et al. (14) reported that in lesions invading the lateral margin, the possibility of residual cancer was low. This may be because the EMR/ESD specimen was not fully evaluated histologically. In addition, EMR/ESD is performed using a coagulating device which means that there might not be cells within the margin of the coagulated tissue.
With regard to the depth of invasion, the presence of residual tumor was associated with submucosal and muscle invasion. In particular, the muscle invasion case required EMR with piecemeal dissection.
All lymph node metastasis cases were associated with submucosal tumor. There was no lymph node metastasis in tumors confined to the mucosa.
These results suggest that the depth of invasion deserves greater consideration than positive margin status as an indication for surgery after incomplete EMR/ESD.
Recently there have been a few report regarding extended criteria for EMR/ESD, it is significant especially regarding the application of extended criteria its presence.
The indications for EMR/ESD in our hospital used the ex- The invasion of tumor can be assessed by performing EUS. The accuracy of EUS for gastric cancer from different authors ranges from 64.8% (19) to 92% (20) in T staging and 50%(21) to 90% (22) in N staging. Currently, EUS is the most reliable method in T and N staging of gastric cancer with high accuracy rates. (23) In our results, 9 of 13 cases were diagnosed as mucosal tumors on EUS but only 3 cases were confirmed as mucosal tumors on final pathology. More accurate pretreatment staging by EUS should be undertaken for proper stage-dependent patient management.
In conclusion, the gastrectomy is needed for patients with incomplete resection after EMR/ESD, because of the risk of both residual tumor and lymph node metastasis. Precise T staging is essential to avoid unnecessary procedures. 
